Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vigdis Nygaard

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Translational Oncology|May 17, 2019
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node MetastasesVivi Ann Flørenes, Karine Flem-Karlsen, Erin McFadden, et al.
Acta Oncologica (Stockholm, Sweden)|March 27, 2020
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction studyAnne Hansen Ree, Vigdis Nygaard, Kjetil Boye, et al.
ESMO Open|August 2, 2017
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimateAnne Hansen Ree, Hege G Russnes, Daniel Heinrich, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Translational Oncology|May 17, 2019
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node MetastasesVivi Ann Flørenes, Karine Flem-Karlsen, Erin McFadden, et al.
Acta Oncologica (Stockholm, Sweden)|March 27, 2020
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction studyAnne Hansen Ree, Vigdis Nygaard, Kjetil Boye, et al.
ESMO Open|August 2, 2017
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimateAnne Hansen Ree, Hege G Russnes, Daniel Heinrich, et al.
Pageof 3